Study Shows T2MR’s Sensitive Detection of Platelet Function at Similar or Lower Platelet Counts than Traditional Tests
Paper Provides Novel Insight Into Platelet Biology Not Evident Using Plasma-Based Platelet Aggregation Tests
LEXINGTON, Mass., Jan. 30, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that a new study, “Rapid evaluation of platelet function with T2 magnetic resonance,” was published in the American Journal of Clinical Pathology (AJCP). The study supports the use of T2 Magnetic Resonance (T2MR®) technology as a platform with the potential to provide a more sensitive and biologically relevant read-out of platelet dysfunction than traditional diagnostic methodologies, including Light Transmission Aggregometry (LTA).
"We are very encouraged by this study, as this represents some of the most extensive data for using T2MR technology to measure platelet activity and also shows some important advantages over the current standard of care – LTA," said John McDonough, chief executive officer at T2 Biosystems. “Among those advantages, we saw that T2MR detected platelet function at similar or lower platelet counts than LTA. In addition, it appeared to be more sensitive to residual platelet function than LTA. Further, smaller blood volumes were required, little to no sample preparation was needed and turnaround time to result was faster.”
LTA remains the mainstay method for the measurement of platelet function in diagnosing patients with qualitative platelet disorders (QPDs) and suspected platelet function disorders (PFDs), despite being labor-intensive, being available only in specialized laboratories and requiring particular technical expertise. Additionally, because LTA does not involve activation of coagulation, it assesses the relationship between platelets and fibrinogen rather than the more physiologically relevant relationship between platelets and fibrin. T2MR is a novel platform that measures hemostasis in whole blood, requires small blood volumes, is technically simple and yields results in minutes. The study published today aimed to develop a more rapid assay for platelet function using T2MR. In addition, it analyzed patients with known platelet dysfunction and then evaluated agreement between T2MR and LTA.
The American Journal of Clinical Pathology paper was published online at http://ajcp.oxfordjournals.org... and appeared in the Volume 146, Issue 6 issue of the journal.
T2 Magnetic Resonance (T2MR) is a diagnostic detection method utilizing miniaturized magnetic resonance technology that measures how water molecules react in the presence of magnetic fields. T2MR is highly sensitive to changes in the microenvironment of a blood sample, such as clot formation, contraction and lysis. This enables the rapid identification of clinically relevant hemostasis changes.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.